Department of Clinical Pharmacy, China Pharmaceutical University, Nanjing, China; Anhui Provincial Center for Drug Clinical Evaluation, Yijishan Hospital of Wannan Medical College, Wuhu, China.
Department of Clinical Pharmacy, China Pharmaceutical University, Nanjing, China.
Pharmacol Rep. 2014 Dec;66(6):1022-30. doi: 10.1016/j.pharep.2014.06.017. Epub 2014 Jul 3.
The antiarrhythmic potential of a novel multichannel blocker CPUY102122 (CY22) was investigated in the present study.
The effect of CY22 on rapid delayed rectifier potassium channel current (IKr) was studied using whole-cell patch clamp techniques in Chinese Hamster Ovary cells stably expressing human Ether-à-go-go-Related Gene. We further evaluated the antioxidant effects of CY22 and demonstrated the reversal of connexin down-regulation in the development of cardiac ventricular arrhythmias, which was produced using coronary ligation/reperfusion in rabbits. CY22 and Amiodarone were administered 30min prior to the procedure. Next, electrocardiograms were recorded, protein expression of left ventricular Connexin43 (Cx43), non-phosphorylation-Cx43 (np-Cx43), Rac-1 and gp-91[phox] were assayed using Western blot analysis, microstructural changes in the myocardium were observed and redox system activity was assayed.
CY22 inhibited IKr in a concentration-dependent manner with IC50 value of 2.8±0.8μmol/L. CY22 treatment significantly decreased T-wave amplitude and QTc arrhythmic scores and ameliorated the shape of the infarcted myocardium compared to the model group. CY22 decreased the serum levels of creatine kinase, lactate dehydrogenase, and myocardial levels of malondialdehyde, as well as increased superoxide dismutase activity. Cx43 expression in the left ventricle was significantly increased by CY22 treatment, which significantly decreased np-43 expression, Rac-1 activity and gp-91[phox] protein expression.
These results indicated that CY22 has both antiarrhythmic and cardiovascular protective effects partly by blocking IKr, the production of antioxidants and protection of Cx43.
本研究旨在探讨新型多通道阻滞剂 CPUY102122(CY22)的抗心律失常作用。
采用全细胞膜片钳技术,在中国仓鼠卵巢细胞中稳定表达人 Ether-à-go-go-Related Gene,研究 CY22 对快速延迟整流钾通道电流(IKr)的影响。进一步评价 CY22 的抗氧化作用,并在兔冠状动脉结扎/再灌注模型中,证明其逆转心脏室性心律失常时连接蛋白下调的作用。CY22 和胺碘酮在手术前 30 分钟给药。然后记录心电图,采用 Western blot 分析测定左心室连接蛋白 43(Cx43)、非磷酸化-Cx43(np-Cx43)、Rac-1 和 gp-91[phox]的蛋白表达,观察心肌微观结构变化,测定氧化还原系统活性。
CY22 呈浓度依赖性抑制 IKr,IC50 值为 2.8±0.8μmol/L。与模型组相比,CY22 治疗可显著降低 T 波振幅和 QTc 心律失常评分,改善梗死心肌形态。与模型组相比,CY22 降低了血清肌酸激酶、乳酸脱氢酶和心肌丙二醛水平,同时增加了超氧化物歧化酶活性。CY22 治疗可显著增加左心室 Cx43 的表达,显著降低 np-43 的表达、Rac-1 活性和 gp-91[phox]蛋白表达。
这些结果表明,CY22 具有抗心律失常和心血管保护作用,部分通过阻断 IKr、产生抗氧化剂和保护 Cx43。